NewsRx

Search our medical news database

Leukemia

Reports from Y.C. Chen and colleagues advance knowledge in leukemia

Published in Cancer Weekly, October 16th, 2007

"Tumor cells with different origins have different threshold to apoptosis. Hematopoietic (Jurkat, NCl-H929) cells and non-hematopoietic (A549, MCF-7) cells were received hyperbaric oxygen (HBO2) treatment from 2.5 to 3.5 atmosphere absolute (ATA) of 100% oxygen for 6 h, and a significant percentage of apoptosis were shown only in hematopoietic Jurkat and NCI-H929 cells by either Annexin V or TUNEL assay," scientists in Taipei, Taiwan report.

"Oxidative stress was illustrated higher in HBO2-treated hematopoietic cells by superoxide fluorochrome detectors. HBO2 treatment leads to caspase-3. caspase-7 activation and further cleavage of PARP within cells," wrote Y.C. Chen...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook